Catalent and AAPS Announce Winners of Annual Academic Competition - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent and AAPS Announce Winners of Annual Academic Competition



The Catalent Applied Drug Delivery Institute and the American Association of Pharmaceutical Scientists (AAPS), reported the winners of their “Global Academic Competition for Life Science Leaders of Tomorrow.” Chosen from US and international universities with graduate programs in pharmaceutical science, the five winners were Maren Preis, University of Dusseldorf, “Regulatory Challenges & Available Dosage Forms”; Prachi Shah, St. Johns University, “Double Emulsions: Scope and Attempts”; Nilesh Gupta, Texas Tech University, “Challenges in Developing Inhalation Technology: Right Particle Size and Device Selection”; Tannaz Ramezanli, Rutgers University, “Stem Cells as Novel Carriers for Cancer Therapy”; and Emrah Ilker Ozay, UMass Amherst, “Slipping through the blood brain barrier with cell penetrating peptide mimics.”

Each winner will receive a cash prize of $2,000 and annual membership to the AAPS. The annual competition aims to identify emerging scientific talent, foster drug delivery education, and reward academic excellence. Competition entries consisted of original review articles addressing topics such as drug development, delivery technologies, improving therapeutic profiles and bioavailability, preformulation, and pediatric drugs.

Source: Catalent Applied Drug Delivery Institute

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here